Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
1-2 May 2018

13th Annual Neurotech Investing & Partnering Conference

Renaissance Waterfront Hotel

MA

United States

27 April 2018

Oryzon to present at upcoming international conferences

9 April 2018

Oryzon to present at upcoming international conferences

4 April 2018

ORYZON receives approval to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

4 April 2018

Annual General Shareholders Meeting 2018

Hotel Eurostars Madrid Tower, en el Paseo de la Castellana 259-B

Spain

5 March 2018

ORYZON Announces Publication of Paper in Cancer Cell establishing the relevance of ORY-1001 as an antileukemic differentiating drug

21 February 2018

Oryzon to present at upcoming international conferences

19 February 2018

Oryzon revamps its Board with an expert in Biomedicine and Epigenetics in the US industry

19 February 2018

ORYZON Reports Financial Results and Corporate Update for the 4th Quarter and Year Ended December 31, 2017

5 February 2018

ORYZON Appoints Clinical Development Leader Lori A. Kunkel, M.D., as a Scientific Advisor

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 39
  • Page 40
  • Page 41
  • Page 42
  • Current page 43
  • Page 44
  • Page 45
  • Page 46
  • Page 47
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel